Upper gastrointestinal obstruction associated with Claritin-D 24 Hour Extended Release tablets.
Farinas
E
E
Division of Pharmacovigilance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD 20857, USA.
Honig
P
P
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D004940:Esophageal Stenosis / Q000150:complications; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007415:Intestinal Obstruction / Q000139:chemically induced* / Q000175:diagnosis; D017336:Loratadine / Q000008:administration & dosage / Q000009:adverse effects*
D003692:Delayed-Action Preparations; D006634:Histamine H1 Antagonists; D017336:Loratadine